Overview
Portfolio 18
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Oct 9, 2025 | nChroma Bio | nchromabio.com | United States, Massachusetts, Cambridge | |
| Aug 8, 2024 | Eledon Pharmaceuticals, Inc. | eledon.com | United States, California, Irvine | |
| Aug 8, 2024 | Leal Therapeutics | lealtx.com | $75M | United States |
| Aug 8, 2024 | Autobahn Therapeutics, Inc. | autobahntx.com | $176M | United States, California, San Diego |
| Aug 8, 2024 | Metsera | metsera.com | $505M | United States |
| May 18, 2023 | Myeloid Therapeutics | myeloidtx.com | $123M | United States, Massachusetts, Cambridge |
| Apr 26, 2023 | Orbital Therapeutics | orbitaltx.com | $270M | United States, Massachusetts, Cambridge |
| Chroma Medicine | chromamedicine.com | $260M | United States, Massachusetts, Cambridge | |
| Kisbee Therapeutics | kisbeetx.com | United States, Massachusetts, Watertown |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 8, 2021 | There are more private equity exits than there have been in 2 decades. How long will it last? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s a great time to get out. Paid Content Optimizing Kubernetes for business security, scalabili... |
Reviews 0
FAQ about Newpath Management
How many startups has Newpath Management invested in?
Newpath Management has 18 portfolio companies on Parsers VC, among them nChroma Bio, Eledon Pharmaceuticals, Inc. and Leal Therapeutics.
What has the press written about Newpath Management?
Parsers VC has collected 2 articles mentioning Newpath Management, among them “There are more private equity exits than there have been in 2 decades. How long will it last?” (Dec 8, 2021).
Is Newpath Management still active?
Yes, Newpath Management is active; its latest activity on Parsers VC dates from Nov 7, 2025.